INVA
Price
$18.91
Change
-$0.30 (-1.56%)
Updated
Jul 7, 04:59 PM (EDT)
Capitalization
1.21B
23 days until earnings call
KALV
Price
$15.06
Change
+$3.08 (+25.71%)
Updated
Jul 7, 04:59 PM (EDT)
Capitalization
595.59M
Earnings call today
Interact to see
Advertisement

INVA vs KALV

Header iconINVA vs KALV Comparison
Open Charts INVA vs KALVBanner chart's image
Innoviva
Price$18.91
Change-$0.30 (-1.56%)
Volume$43.29K
Capitalization1.21B
KalVista Pharmaceuticals
Price$15.06
Change+$3.08 (+25.71%)
Volume$129.43K
Capitalization595.59M
INVA vs KALV Comparison Chart in %
Loading...
INVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INVA vs. KALV commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INVA is a Buy and KALV is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (INVA: $19.21 vs. KALV: $11.98)
Brand notoriety: INVA and KALV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INVA: 72% vs. KALV: 43%
Market capitalization -- INVA: $1.21B vs. KALV: $595.59M
INVA [@Biotechnology] is valued at $1.21B. KALV’s [@Biotechnology] market capitalization is $595.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INVA’s FA Score shows that 1 FA rating(s) are green whileKALV’s FA Score has 0 green FA rating(s).

  • INVA’s FA Score: 1 green, 4 red.
  • KALV’s FA Score: 0 green, 5 red.
According to our system of comparison, INVA is a better buy in the long-term than KALV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INVA’s TA Score shows that 6 TA indicator(s) are bullish while KALV’s TA Score has 2 bullish TA indicator(s).

  • INVA’s TA Score: 6 bullish, 4 bearish.
  • KALV’s TA Score: 2 bullish, 8 bearish.
According to our system of comparison, INVA is a better buy in the short-term than KALV.

Price Growth

INVA (@Biotechnology) experienced а -5.79% price change this week, while KALV (@Biotechnology) price change was +4.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.35%. For the same industry, the average monthly price growth was +13.82%, and the average quarterly price growth was -0.82%.

Reported Earning Dates

INVA is expected to report earnings on Jul 30, 2025.

KALV is expected to report earnings on Jul 07, 2025.

Industries' Descriptions

@Biotechnology (+5.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INVA($1.21B) has a higher market cap than KALV($596M). KALV YTD gains are higher at: 41.440 vs. INVA (10.720). INVA has higher annual earnings (EBITDA): 681K vs. KALV (-173.23M). INVA has more cash in the bank: 447M vs. KALV (253M). KALV has less debt than INVA: KALV (5.78M) vs INVA (451M). INVA has higher revenues than KALV: INVA (370M) vs KALV (0).
INVAKALVINVA / KALV
Capitalization1.21B596M202%
EBITDA681K-173.23M-0%
Gain YTD10.72041.44026%
P/E Ratio51.97N/A-
Revenue370M0-
Total Cash447M253M177%
Total Debt451M5.78M7,800%
FUNDAMENTALS RATINGS
INVA vs KALV: Fundamental Ratings
INVA
KALV
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
53
Fair valued
PROFIT vs RISK RATING
1..100
5998
SMR RATING
1..100
9399
PRICE GROWTH RATING
1..100
5554
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KALV's Valuation (53) in the Pharmaceuticals Other industry is in the same range as INVA (74). This means that KALV’s stock grew similarly to INVA’s over the last 12 months.

INVA's Profit vs Risk Rating (59) in the Pharmaceuticals Other industry is somewhat better than the same rating for KALV (98). This means that INVA’s stock grew somewhat faster than KALV’s over the last 12 months.

INVA's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as KALV (99). This means that INVA’s stock grew similarly to KALV’s over the last 12 months.

KALV's Price Growth Rating (54) in the Pharmaceuticals Other industry is in the same range as INVA (55). This means that KALV’s stock grew similarly to INVA’s over the last 12 months.

INVA's P/E Growth Rating (2) in the Pharmaceuticals Other industry is significantly better than the same rating for KALV (100). This means that INVA’s stock grew significantly faster than KALV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INVAKALV
RSI
ODDS (%)
Bullish Trend 5 days ago
69%
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
65%
Bullish Trend 5 days ago
84%
Momentum
ODDS (%)
Bearish Trend 5 days ago
62%
Bearish Trend 5 days ago
85%
MACD
ODDS (%)
Bearish Trend 5 days ago
46%
Bearish Trend 5 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
60%
Bullish Trend 5 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
61%
Bearish Trend 5 days ago
87%
Advances
ODDS (%)
Bullish Trend 22 days ago
67%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
63%
Bearish Trend 8 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
86%
Bearish Trend 5 days ago
86%
Aroon
ODDS (%)
Bullish Trend 5 days ago
69%
Bearish Trend 5 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
INVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BMGKX45.580.48
+1.06%
BlackRock Mid-Cap Growth Equity K
PSECX18.720.10
+0.54%
1789 Growth and Income C
VBPIX21.960.09
+0.41%
Vanguard Baillie GiffordGlbPstvImpStkInv
JNRRX56.170.04
+0.07%
PGIM Jennison Natural Resources R
DIFHX12.38N/A
N/A
MFS Diversified Income R6

INVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, INVA has been loosely correlated with GBIO. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if INVA jumps, then GBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INVA
1D Price
Change %
INVA100%
-0.98%
GBIO - INVA
38%
Loosely correlated
+1.51%
INBX - INVA
37%
Loosely correlated
+3.75%
KALV - INVA
36%
Loosely correlated
+1.70%
CPRX - INVA
36%
Loosely correlated
+0.05%
SCPH - INVA
36%
Loosely correlated
-1.73%
More

KALV and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with IDYA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
+1.70%
IDYA - KALV
47%
Loosely correlated
+0.82%
ATXS - KALV
46%
Loosely correlated
+1.40%
TRDA - KALV
46%
Loosely correlated
N/A
IRON - KALV
46%
Loosely correlated
+7.08%
ERAS - KALV
44%
Loosely correlated
-0.69%
More